We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment

By LabMedica International staff writers
Posted on 14 Mar 2024

Melioidosis, a neglected tropical disease, is believed to affect around 165,000 individuals globally each year, with approximately 89,000 succumbing to it. More...

This illness is caused by the bacterium Burkholderia pseudomallei, which thrives in the soil and water of tropical and subtropical areas, gaining entry into humans through skin cuts, consumption, or inhalation. Diagnosing melioidosis poses challenges due to its varying symptoms ranging from localized infections and pneumonia to severe septicemia or prolonged chronic conditions. The disease's tendency to predominantly affect isolated rural communities contributes to its significant underreporting. Diagnosis traditionally depends on culturing bacterial specimens, a process extending over three to four days. Meanwhile, a large percentage of patients with melioidosis succumb to the disease, often within the initial 24 to 48 hours of hospital admission, while waiting for a diagnosis. Although no vaccine exists for melioidosis, it can be effectively managed with specific intravenous antibiotics if identified promptly. However, the current diagnostic delay leads to the initial administration of broad-spectrum antibiotics, unnecessarily extending treatment times and resource usage.

An international collaboration that included researchers from the Wellcome Sanger Institute (Cambridgeshire, UK) has led to the development of a rapid diagnostic test capable of identifying melioidosis within hours, significantly quicker than traditional methods. This advancement allows for the faster administration of appropriate antibiotics. Utilizing CRISPR technology, this new test identifies a Burkholderia pseudomallei-specific genetic marker with 93% sensitivity, offering a promise of higher survival rates through a rapid, globally applicable diagnostic solution. Developing this test involved the analysis of over 3,000 B. pseudomallei genomes, predominantly sequenced at the Sanger Institute, to identify a unique genetic target.

The designed test, CRISPR-BP34, enhances the DNA of the target bacterium through a recombinase polymerase amplification reaction, with a subsequent CRISPR reaction ensuring specificity. The presence of melioidosis is confirmed by a simple lateral flow 'dipstick' method. To validate this test, the team examined clinical samples from 114 melioidosis patients and 216 non-affected individuals from northeast Thailand, a melioidosis hotspot. The CRISPR-BP34 test demonstrated a 93% sensitivity rate, surpassing the 66.7% sensitivity of conventional bacterial culture techniques, and delivered results within four hours for urine, pus, and sputum samples, and within a day for blood samples, markedly faster than the current methods. This new rapid diagnostic test not only promises quicker diagnosis and treatment for melioidosis patients but also aims to conserve medical resources and reduce hospital stays by preventing the indiscriminate use of broad-spectrum antibiotics. The team is planning randomized clinical trials to further validate the test's effectiveness in hospitals and is exploring the influence of human genetics on melioidosis susceptibility and immune response.

“This research is a testament to international collaboration and how the application of genomics at scale leads to clinical intervention,” said Professor Nick Thomson, Head of Parasites and Microbes at the Wellcome Sanger Institute. “Using a genetic target mined from a bank of thousands of bacterial genomes, the team was able to produce an incredibly sensitive test that is specific to the bacterium behind melioidosis. I look forward to seeing the clinical impacts of this research.”

Related Links:
Wellcome Sanger Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.